Company profile: BCF Life Sciences
1.1 - Company Overview
Company description
- Provider of natural amino acids and derivatives for the pharmaceutical and health care industries. Specialises in extracting L-Cystine and L-Tyrosine of 100% traced origin and derivatives such as Carbocisteine. Offers L-Cystine, L-Tyrosine, Carbocisteine (expectorant API), Cysti-White, Kera-Diet keratin hydrolysate, and Leafamine (17 free amino acids) for food supplements, baby foods, and sustainable agriculture.
Products and services
- Carbocistein: A pharmaceutical active ingredient synthesized from L-Cystine for expectorant syrup formulations, 100 % traced origin derivative intended for healthcare applications
- L-Cystine: A natural amino acid of 100 % traced origin employed in food supplements to support hair and nail growth and vitality
- L-Tyrosine: A natural amino acid of 100 % traced origin deployed in food supplements to stimulate cognitive functions and help manage stress
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BCF Life Sciences
QInstruments
HQ: Germany
Website
- Description: Provider of industry-leading Life Science mixing technology and sample preparation products, supporting pharmaceutical research. Serves life-science research laboratories, university medical centers, and drug discovery laboratories in pharmaceutical and biotechnology firms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QInstruments company profile →
Immunicon
HQ: United States
Website
- Description: Provider of proprietary cell-based research and diagnostic products focused on cancer, offering a PET/CT Center using PET/CT and CT imaging for precision diagnosis of cancer and dementia, biomarker research on HER2, PD-L1, FGFR2b, CLDN18.2, and MSI, and resources on treating HER2-positive cancers, including breast and biliary tract cancers. Their offerings help physicians understand, diagnose, treat, and monitor cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunicon company profile →
Ziylo
HQ: United Kingdom
Website
- Description: Provider of biomimetic glucose binding molecules (GBM) based on supramolecular chemistry for use in diabetes care, enabling Continuous Glucose Monitors (CGM) and Glucose Responsive Insulins (GRI), with a mission to help people with diabetes live more normal and longer lives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ziylo company profile →
ALK
HQ: Denmark
Website
- Description: Provider of allergy treatments, vaccination, and immunotherapy, offering SLIT tablets and drops for common respiratory allergies (house dust mite, grass, birch-family trees, ragweed, Japanese cedar), immunotherapy that addresses underlying causes and allergic asthma, a web shop and klarify.me with drug-free products/services, and a developing peanut allergy tablet.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ALK company profile →
Semba Biosciences
HQ: United States
Website
- Description: Provider of innovative instruments, reagents, methods, and solutions for high-performance purification of biomolecules and chemicals, serving the worldwide research community.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Semba Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BCF Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BCF Life Sciences
2.2 - Growth funds investing in similar companies to BCF Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BCF Life Sciences
4.2 - Public trading comparable groups for BCF Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →